A phase II study of ifosfamide and a 2b -interferon in advanced non-small-cell lung cancer Academic Article uri icon

Overview

MeSH Major

  • Carcinoma, Non-Small-Cell Lung
  • Ifosfamide
  • Interferon-alpha
  • Lung Neoplasms

abstract

  • A total of 45 patients with advanced non-small-cell lung cancer were treated with a combination of 1.5 g/m2 ifosfamide given on days 1-5 every 3 weeks for four courses with 3 million IU a2b-interferon (Intron A) given s.c. three times a week for 12 weeks. Nine objective responses were seen, including two complete responses (CRs) and seven partial responses (PRs). Haematological and non-haematological toxicities were generally mild and did not necessitate discontinuation of therapy.

publication date

  • March 1991

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1007/BF00689705

PubMed ID

  • 1647893

Additional Document Info

start page

  • 142

end page

  • 4

volume

  • 28

number

  • 2